Have a feature idea you'd love to see implemented?
Let us know!
CRSP CRISPR Therapeutics AG
Price (delayed)
$52.33
Market cap
$4.47B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.8
Enterprise value
$4.46B
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that
Highlights
CRSP's quick ratio is up by 38% QoQ and by 38% YoY
The EPS is up by 37% year-on-year and by 13% since the previous quarter
The equity has increased by 12% YoY but it has decreased by 2.1% QoQ
Key stats
What are the main financial stats of CRSP
Market
Valuations
Earnings
Shares outstanding
85.35M
Market cap
$4.47B
Enterprise value
$4.46B
Price to book (P/B)
2.3
Price to sales (P/S)
21.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.97
Revenue
$202.83M
EBIT
-$236.47M
EBITDA
-$217.16M
Free cash flow
-$191.2M
Per share
Balance sheet
Liquidity
EPS
-$2.8
Free cash flow per share
-$2.24
Book value per share
$22.77
Revenue per share
$2.38
TBVPS
$26.47
Total assets
$2.26B
Total liabilities
$316.47M
Debt
$227.55M
Equity
$1.94B
Working capital
$1.85B
Debt to equity
0.12
Current ratio
21.64
Quick ratio
21.68
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-107.1%
Gross margin
100%
Net margin
-118.1%
Operating margin
-163.9%
Return on assets
-10.3%
Return on equity
-12.2%
Return on invested capital
-12%
Return on capital employed
-10.9%
Return on sales
-116.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRSP stock price
How has the CRISPR Therapeutics AG stock price performed over time
Intraday
5.7%
1 week
2.27%
1 month
3.17%
1 year
-26.44%
YTD
-16.41%
QTD
11.39%
Financial performance
How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$202.83M
Gross profit
$202.83M
Operating income
-$332.39M
Net income
-$239.59M
Gross margin
100%
Net margin
-118.1%
The net margin has increased by 43% year-on-year and by 10% since the previous quarter
The operating margin is up by 34% year-on-year and by 7% since the previous quarter
The company's net income rose by 32% YoY and by 10% QoQ
The company's operating income rose by 22% YoY and by 6% QoQ
Growth
What is CRISPR Therapeutics AG's growth rate over time
Valuation
What is CRISPR Therapeutics AG stock price valuation
P/E
N/A
P/B
2.3
P/S
21.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.97
The EPS is up by 37% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 26% lower than the 5-year quarterly average of 3.1 and 4.2% lower than the last 4 quarters average of 2.4
The equity has increased by 12% YoY but it has decreased by 2.1% QoQ
The price to sales (P/S) is 98% lower than the 5-year quarterly average of 1298.4 but 15% higher than the last 4 quarters average of 19.1
The revenue has grown by 19% year-on-year
Efficiency
How efficient is CRISPR Therapeutics AG business performance
The return on sales is up by 45% year-on-year and by 10% since the previous quarter
The ROE has grown by 37% YoY and by 12% from the previous quarter
The company's return on assets rose by 36% YoY and by 12% QoQ
The ROIC rose by 36% YoY and by 15% QoQ
Dividends
What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRSP.
Financial health
How did CRISPR Therapeutics AG financials performed over time
CRSP's quick ratio is up by 38% QoQ and by 38% YoY
CRISPR Therapeutics AG's current ratio has increased by 38% from the previous quarter and by 37% YoY
The debt is 88% smaller than the equity
CRSP's debt to equity is down by 14% YoY
The equity has increased by 12% YoY but it has decreased by 2.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.